Skip to main content

Table 1 Patient characteristics at baseline (N =77)

From: Capecitabine and irinotecan with bevacizumab 2-weekly for metastatic colorectal cancer: the phase II AVAXIRI study

Sex

N

%

Male

51

66.2

Female

26

33.8

Median age, years (range)

65 (41–81)

ECOG performance status

N

%

0

46

59.7

1

28

36.4

2

3

3.9

Location of primary tumour

N

%

Rectum

24

31.2

Colon

41

53.2

Colon and rectum

12

15.6

No. of lesions

N

%

1

6

7.8

2

13

16.9

≥3

58

75.4

Prior therapy

N

%

Surgery

50

64.9

Adjuvant chemotherapy

27

35.1

Radiotherapy

9

11.7

Metastatic site

N

%

Liver

48

62.3

Lung

42

54.5

Local

18

23.4

Other

27

35.1

Organs with metastases

N

%

1

31

40.3

2

32

41.6

≥3

14

18.2

  1. Abbreviation: ECOG Eastern Cooperative Oncology Group.